TITLE

Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas

AUTHOR(S)
McKenzie, Shaun; Lee, Wendy; Artinyan, Avo; Mailey, Brian; Pigazzi, Alessio; Ellenhom, Joshua; Kim, Joseph; Ellenhorn, Joshua
PUB. DATE
November 2010
SOURCE
Journal of Gastrointestinal Surgery;Nov2010, Vol. 14 Issue 11, p1796
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Introduction: The role of multidisciplinary management of islet cell cancers (ICC) has not been fully investigated in a population-based setting.Methods: The Los Angeles County Cancer Surveillance Program was assessed for patients with ICC between the years 1982 to 2006. Patients were stratified by treatment received and clinicopathologic characteristics and survival were compared.Results: We identified 236 patients with ICC; 86 patients underwent curative-intent surgery with median survival for local, regional, and distant disease of 17.3, 12.2, and 4.0 years, respectively. In comparison, 102 patients underwent medical management alone; survival was significantly shorter when compared to the surgical cohort for local, regional, and distant disease (p < 0.05). To determine whether adjuvant chemotherapy was associated with improved survival, we compared patients who underwent surgery alone compared to patients who underwent surgery followed by adjuvant chemotherapy. Although patients with metastatic disease had 3-year longer survival with adjuvant chemotherapy, these improvements in survival were not statistically significant.Conclusion: Surgical resection was associated with improved survival compared to medical management for any extent of disease in patients with ICC. Furthermore, adjuvant chemotherapy was not associated with survival but does warrant further examination in patients with metastatic disease.
ACCESSION #
54456528

 

Related Articles

  • Improving Long-Term Survival in Patients With Locally Advanced Pancreatic Cancer via the Delivery of Definitive Radiotherapy Doses. CRANE, CHRISTOPHER H. // Oncology;Aug2015, Vol. 29 Issue 8, p561 

    The article discusses long-term survival chance improvement for patients with locally advanced pancreatic cancer through definitive radiotherapy doses. Topics include a comparison between chemoradiation and chemotherapy for locally advanced pancreatic cancer, the importance of local tumor...

  • Effect of Neoadjuvant Nab-Paclitaxel plus Gemcitabine Therapy on Overall Survival in Patients with Borderline Resectable Pancreatic Cancer: A Prospective Multicenter Phase II Trial (NAC-GA Trial). Okada, Ken-ichi; Shimokawa, Toshio; Hirono, Seiko; Kawai, Manabu; Sho, Masayuki; Satoi, Sohei; Matsumoto, Ippei; Eguchi, Hidetoshi; Murakami, Yoshiaki; Yamada, Suguru; Doi, Mariko; Yamaue, Hiroki // Oncology;Oct2017, Vol. 93 Issue 5, p343 

    We conducted a prospective multicenter phase II trial of patients with borderline resectable pancreatic carcinoma to investigate the efficacy of neoadjuvant nab-paclitaxel plus gemcitabine thera py on ov erall survival (OS). The clinical trial primarily evaluated OS time from the first day of...

  • Treatment Strategy for Rectal Cancer with Synchronous Metastasis: 65 Consecutive Italian Cases from the Bologna Multidisciplinary Rectal Cancer Group. Pinto, Carmine; Pini, Sara; Di Fabio, Francesca; Cuicchi, Dajana; Iacopino, Bruno; Lecce, Ferdinando; Ercolani, Giorgio; Rojas Llimpe, Fabiola Lorena; De Raffele, Emilio; Stella, Franco; Di Tullio, PierGiorgio; Giaquinta, Stefania; Pinna, Antonio Daniele; Cola, Bruno // Oncology;May2014, Vol. 86 Issue 3, p135 

    Background: Twenty percent of rectal cancer patients have synchronous distant metastasis at diagnosis. At present, the treatment strategy in this patient setting is not well defined. This study in one institution evaluates the treatment strategy of three different patient groups. Patients and...

  • New Advance in Pancreatic Cancer. Jurasunas, Serge // Townsend Letter;Aug/Sep2009, Issue 313/314, p82 

    The article looks at the case of a 52-year-old Caucasian female who was diagnosed with an advanced metastatic pancreatic cancer. It notes the resistance of the disease to various treatments, including chemotherapy. The combination therapy for the treatment of pancreatic cancer is also discussed,...

  • Adjuvant Therapy Reduces Rate of Dissemination but Shortens Survival Thereafter. Fink, Michael K.; Kleeberg, Ulrich R.; Bartels, Stefan // Oncologist;2015, Vol. 20 Issue 7, following p736 

    In the subgroup of patients who suffer from metastases despite adjuvant therapy, survival after dissemination is shortened. This is partially due to an adjuvant chemotherapy‐induced resistance to previous treatment and may be similar after hormonal therapy and immunotherapy.

  • Induction Chemotherapy with Docetaxel, Cisplatin and Capecitabine, Followed by Combined Cetuximab and Radiotherapy in Patients with Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck: A Phase I-II Study. Perri, Francesco; Muto, Paolo; Argenone, Angela; Ionna, Franco; Longo, Francesco; Fulciniti, Franco; Sandomenico, Fabio; Daponte, Antonio; Caponigro, Francesco // Oncology;Mar2013, Vol. 84 Issue 4, p251 

    Objectives: To replace 5-fluorouracil with capecitabine within a trial of induction chemotherapy followed by cetuximab plus radiotherapy (RT) in patients with locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Also, to replace cisplatin with cetuximab after induction...

  • Early Detection of Pancreatic Glucagonoma. Haga, Yoshio; Yanagi, Hidetaka; Urata, Jouji; Inada, Masayuki; Shimada, Shinya; Nitahata, Nagomu; Tanimura, Masanori // American Journal of Gastroenterology;Dec1995, Vol. 90 Issue 12, p2216 

    Glucagonoma is a rare islet cell tumor of pancreas. Only 122 proven cases have been reported in the English literature so far. Diagnosis of glucagonoma has usually been delayed. The average size of clinically detected glucagonomas was 5.8 cm, and 54.7% of them exhibited metastasis. We describe...

  • Lynparza Indicated for Maintenance Treatment of Metastatic Pancreatic Cancer with BRCA Mutation.  // American Health & Drug Benefits;2020Special issue, Vol. 12, p11 

    The article offers information on Food and Drug Administration approval of a new indication for Lynparza for the maintenance treatment of adults with metastatic pancreatic adenocarcinoma associated with a deleterious or suspected deleterious germline BRCA mutation.

  • Selected anti-tumor vaccines merit a place in multimodal tumor therapies. Weiss, Eva-Maria; Wunderlich, Roland; Ebel, Nina; Rubner, Yvonne; Schlücker, Eberhard; Meyer-Pittroff, Roland; Ott, Oliver J.; Fietkau, Rainer; Gaipl, Udo S.; Frey, Benjamin // Frontiers in Oncology;Oct2012, Vol. 2, p1 

    Multimodal approaches are nowadays successfully applied in cancer therapy. Primary locally acting therapies such as radiotherapy (RT) and surgery are combined with systemic administration of chemotherapeutics. Nevertheless, the therapy of cancer is still a big challenge in medicine. The...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics